|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Given that the function of any PSi-based biosensor is highly dependent on its nanomorphology, we systematically optimized a PSi biosensor based on reflectometric interference spectroscopy (RIS) detecting the high penetrance breast cancer susceptibility gene, BRCA1.
|
30124007 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Associations between female reproductive factors and breast cancer risk have been widely studied in the general population and BRCA1/2 mutation carriers but not in LFS.
|
31212162 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Our findings show that those at low risk of carrying a BRCA1/2 mutation had limited understanding of the distinction between mutation risk and breast cancer risk.
|
31597139 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D.
|
30552672 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
We show that pregnancy triggers replicative stresses leading to genetic instability in mice carrying a mammary specific disruption of breast cancer associated gene-1 (BRCA1).
|
30445628 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Finding the differences between these two types of breast cancer (non-BRCA1/A2 and BRCA1/A2) at genomic, transcriptomic, and proteomic levels can help us to elucidate fundamental molecular processes and develope more promising therapeutic targets.
|
30125992 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Genetic predisposition, such as breast cancer 1 (BRCA1) mutations, account for a minor percentage of the total breast cancer incidences.
|
31690802 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
BRCA 1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
|
30561604 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the breast cancer risk association of these two FANCC variants, if any, is much smaller than for BRCA1, BRCA2 or PALB2 mutations.
|
31467304 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Here we show that RD-N treatment drives CTSB translocation from the lysosomes to the nucleus where it promotes DNA damage by suppression of the breast cancer 1 protein (BRCA1).
|
30565390 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Women who inherit a BRCA1 or BRCA2 mutation have an increased risk of breast cancer.
|
31407530 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
These myoepithelial perturbations in normal breast tissues of BRCA1 germline mutation carriers may play a role in their higher risk of breast cancer.
|
31519911 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The present study aimed to investigate the effect of the combined treatment with cisplatin and radiation therapy on the biological characteristics of the osteosarcoma cell line MG-63 and the breast cancer 1 (BRCA1)-associated signaling pathways.
|
31807162 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Western Analysis of Breast Cancer 1 Protein (BRCA1).
|
31069686 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Compound 81, an isoform-selective PARP-1/-2 (IC<sub>50</sub> = 30 nM/2 nM) inhibitor, demonstrated selective cytotoxic effect toward breast cancer gene 1 ( BRCA1)-deficient cells compared to isogenic BRCA1-proficient cells.
|
31042381 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
However, it is still unclear how BRCA1 and CCND1 expression levels affect the effect of T cell activation on breast cancer patient survival.
|
31023256 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Breast cancer gene 1 (BRCA1) is a tumor suppressor that is associated with hereditary breast and ovarian cancer.
|
30617304 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to estimate the efficiency of providing germline BRCA1/2 testing to high-grade epithelial ovarian cancer (HGEOC) patients without family history of OC or BC and the subsequent testing and management of their relatives with gBRCA1/2m in Spain.
|
30617925 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Women with an inherited germline BRCA1 mutation have a high lifetime risk of developing breast cancer.
|
30612273 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We searched for germline mutations in the TP53 gene using targeted next-generation sequencing (NGS) in 78 BC patients younger than 45 years old (yo) who tested negative for BRCA1/2 mutations.
|
30709381 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Here we investigated the impact of the absence of PARP3 or its inhibition on the tumorigenicity of BRCA1-proficient versus BRCA1-deficient breast cancer cell lines, focusing on the triple-negative breast cancer subtype (TNBC).
|
30442946 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Therefore, features of genomic instability such as that mediated by BRCA1- and BRCA2- deficiency in breast cancer were necessary, but not always sufficient, for yielding T cell-inflamed tumour microenvironment, and by extension, predicting clinical benefit from immunotherapy.
|
31022191 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
|
30904701 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The present study aimed to investigate BRCA1 and FANCD2 expression in breast cancer, and to highlight the association with patient clinical characteristics and prognoses.
|
30881493 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
There were no significant differences in disease-free survival, overall survival, or breast cancer-specific survival (p = 0.799, 0.092, and 0.124, respectively) between BRCA 1/2 carriers and non-carriers, although BRCA 1/2 carriers showed significantly worse contralateral breast cancer-free survival (p < 0.0001) than non-carriers.
|
30350268 |
2019 |